Prostate cancer diagnostic guidelines undergo changes in Australia and the UK

Australia has introduced its first major overhaul of prostate cancer early detection guidelines in a decade. The new NHMRC-approved framework, developed by the Prostate Cancer Foundation of Australia, shifts the diagnostic focus toward identifying clinically significant disease while attempting to minimize unnecessary biopsies and treatments. Key changes include a greater emphasis on individual risk, shared decision-making, and the use of multiparametric MRI (mpMRI) in the diagnostic pathway.

In the United Kingdom, new guidance from the Department of Health and Social Care has drawn criticism following a shift in how prostate-specific antigen (PSA) tests are administered. The updated approach moves away from widespread screening for all men over 50, instead granting GPs the authority to decide if a test is necessary based on individual cancer risk. Critics and public figures, including former Prime Minister David Cameron, have described the move as a ‘backwards step’ that may lead to later diagnoses.